Nanomedicine’s research focuses on the development of diagnostics tools and solutions towards an early and unequivocal diagnosis of cancer, cardiovascular and ageing-associated diseases. Nanomedicine works in close collaboration with the clinic to enable translational medical research and to approach the end-user, in an attempt to offer a better prognosis and personalized treatment. To this aim, Nanomedicine covers the engineering of advanced (magnetic) theranostic nanostructures and liquid biopsy-based biomicrofluidic devices, the development of bio-imaging tools based on the identification and validation of diseases’ biomarkers and the study of cellular interactions at the tumor microenvironment and metastatic sites, ranging from low to high TRLs.
Nanomedicine evolves in the frontier between different disciplines of knowledge, such as chemistry, materials science, physics and biology, always within an international framework.
1- Engineering of advanced (magnetic) nanostructures towards in vivo disease-targeted diagnosis and stimuli-assisted therapy and theranostics. Leaded by Manuel Bañobre.
2- Development of in vivo imaging tools based on the identification and validation of inflammatory biomarkers as indicators of cardiovascular diseases. Leaded by Marina Brito.
3- Nanobioengineering of microfluidic devices focused on liquid biopsy, mainly centered on the isolation and characterization of tumor cells from the body fluids of cancer patients. Leaded by Lorena Diéguez.
4- Development of innovative tools to study cellular interactions at the tumor microenvironment and metastatic sites. Leaded by Marina Brito.
Lorena G. Hevia